Brokerages Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) PT at $25.71

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have received a consensus rating of “Buy” from the nine analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $25.71.

A number of analysts recently issued reports on KYTX shares. HC Wainwright lowered their price target on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, November 20th. Rodman & Renshaw began coverage on Kyverna Therapeutics in a research report on Wednesday, October 9th. They set a “buy” rating and a $16.00 target price on the stock. Wells Fargo & Company reduced their price target on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, November 15th. UBS Group started coverage on Kyverna Therapeutics in a report on Thursday, October 10th. They issued a “buy” rating and a $13.00 price objective on the stock. Finally, RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th.

Institutional Trading of Kyverna Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in shares of Kyverna Therapeutics by 15.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,387,352 shares of the company’s stock valued at $11,674,000 after purchasing an additional 326,095 shares during the last quarter. Franklin Resources Inc. boosted its stake in Kyverna Therapeutics by 13.8% during the third quarter. Franklin Resources Inc. now owns 936,961 shares of the company’s stock worth $4,582,000 after buying an additional 113,922 shares during the period. Barclays PLC boosted its stake in Kyverna Therapeutics by 21.5% during the third quarter. Barclays PLC now owns 70,167 shares of the company’s stock worth $343,000 after buying an additional 12,418 shares during the period. Geode Capital Management LLC increased its position in shares of Kyverna Therapeutics by 19.0% during the third quarter. Geode Capital Management LLC now owns 443,312 shares of the company’s stock valued at $2,168,000 after acquiring an additional 70,714 shares during the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Kyverna Therapeutics by 78.3% in the 3rd quarter. Jane Street Group LLC now owns 39,193 shares of the company’s stock valued at $192,000 after acquiring an additional 17,215 shares during the period. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Performance

Shares of KYTX stock opened at $3.99 on Wednesday. The business has a fifty day moving average of $4.77 and a 200 day moving average of $6.46. Kyverna Therapeutics has a 1 year low of $3.63 and a 1 year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.01. The business had revenue of $0.01 million during the quarter. Equities research analysts anticipate that Kyverna Therapeutics will post -3.29 EPS for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.